Phase II
The National Institutes of Health ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.
The company plans to present detailed study results from the WILLOW study at an upcoming medical meeting.
United Therapeutics announced that its Phase II/III DISTINCT trial failed to meet its primary efficacy endpoint.
No treatments are currently approved for the disease.
Pharma companies from across the globe provide updates on their pipelines and business.
The company based the decision on safety information after unexpected serious adverse events, including one patient death in its Phase IIb CATALYST trial.
The Phase II multicenter, randomized, double-blind, placebo-controlled, dose-ranging study included 105 patients with hypertriglyceridemia, type 2 diabetes and NAFLD.
Epygenix Therapeutics, Inc. announced that the Company successfully completed a Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to assess safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 in fasting healthy subjects and following a high-fat meal.
Habib Dable, president and chief executive officer of Acceleron, said he was “thrilled” about the positive results from the mid-stage PULSAR trial.
In addition to various deal news, AstraZeneca had clinical trial news today as well.
PRESS RELEASES